Glucose intolerance: The hidden danger in hypertensives!

International Angiology

Volumn 24, Issue 3, 2005, Pages 207-214

  Salmasi, A Majeed ^a   Dancy, M ^a  

^a CENTRAL MIDDLESEX HOSPITAL   (United Kingdom)

Author keywords

Arterial stiffness; Diabetes mellitus; Hypertension; Impaired glucose tolerance; Left ventricular hypertrophy

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C;

ARTERIOSCLEROSIS; CARDIOVASCULAR RISK; COMORBIDITY; DIABETES MELLITUS; DIASTOLE; DISORDERS OF CARBOHYDRATE METABOLISM; GLUCOSE BLOOD LEVEL; GLUCOSE INTOLERANCE; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEMOGLOBIN DETERMINATION; HUMAN; HYPERTENSION; IMPAIRED GLUCOSE TOLERANCE; MORTALITY; ORAL GLUCOSE TOLERANCE TEST; PRIMARY PREVENTION; REVIEW; RISK ASSESSMENT; SENSITIVITY ANALYSIS;

ARTERIES; CARDIOVASCULAR DISEASES; COMORBIDITY; DIABETIC ANGIOPATHIES; ELASTICITY; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE TEST; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; RISK FACTORS;

EID: 27744549975     PISSN: 03929590     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (76)

1. Ezzati M, Lopez AD, Rodgers A, Vander Hoorn S, Murray CJ, Comparative Risk Assessment Collaborating Group. Selected major risk factors and global and regional burden of disease. Lancet 2002;360:1347-60.
2. Kannel WB. Blood pressure as a cardiovascular risk factor: prevention and treatment. JAMA 1996;275:1571-6.
3. Kannel WB, Dannenberg AL, Abbott RD. Unrecognised myocardial infarction and hypertension: the Framingham study. Am Heart J 1985;109:581-5.
4. Havlik RJ, LaCroix AZ, Kleinman JC, Ingram DD, Harris T, Cornoni-Huntley J. Antihypertensive drug therapy and survival by treatment status in a national survey. Hypertension 1989; 13(5 Suppl):128-32.
5. Fuller JH, Shipley MJ, Rose G, Jarrett RJ, Keen H. Coronary heart disease risk and impaired glucose tolerance: the Whitehall study. Lancet 1980;I:1373-6.
6. Rytter L, Troelsen S, Beck-Nielsen H. Prevalence and mortality of acute myocardial infarction in patients with diabetes. Diabetes Care 1985;8:230-4.
7. Abbud ZA, Shindler DM, Wilson AC, Kostis JB. Effect of diabetes mellitus on short- and long-term mortality rates of patients with acute myocardial infarction: a statewide study. Am Heart J 1995;130:51-8.
8. Ferrannini E, Buzzigoli G, Bonadonna R, Giorico MA, Oleggini M, Graziadei L et al. Insulin resistance in essential hypertension. N Engl J Med 1987;317:350-7.
9. Report of the WHO consultation. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1 Diagnosis and classification of diabetes mellitus. World Health Organisation, Geneva, 1999.
10. Anand SS, Razak F, Vuksan V, Gerstein HC, Malmberg K, Yi Q et al. Diagnostic strategies to detect glucose intolerance in a multiethnic population. Diabetes Care 2003;26:290-6.
11. Williams DR, Wareham NJ, Brown DC, Byrne CD, Clark PM, Cox BD et al. Undiagnosed glucose intolerance in the community: the Isle of Ely Diabetes Project. Diabet Med 1995;12:30-5.
12. Kannel WB. Potency of vascular risk factors as the basis for antihypertensive therapy. Eur Heart J 1992; 13 Suppl G:34-42.
13. Baron AD, Brechtel G, Johnson A, Fineberg N, Henry DP, Steinberg HO. Interactions between insulin and norepinephrine on blood pressure and insulin sensitivity. Studies in lean and obese men. J Clin Invest 1994;93:2453-62.
14. Salmasi AM, Alimo A, Dancy M. Prevalence of unrecognised abnormal glucose tolerance in patients attending a hospital Hypertension Clinic. Am J Hypertens 2004; 17: 483-8.
15. Salmasi AM, Dancy M. The glucose tolerance test, but not HbA1c, remains the gold standard in identifying unrecognised diabetes mellitus and impaired glucose tolerance in hypertensive subjects. Angiology. In press 2005.
16. Bur A, Herkner H, Woisetschlager C, Vlcek M, Derhaschnig U, Hirschl MM. Is fasting blood glucose a reliable parameter for screening for diabetes in hypertension? Am J Hypertens 2003;16:297-301.
17. Salmasi AM, Frost P, Dancy M. Left ventricular diastolic function in normotensive subjects two months after acute myocardial infarction is related to glucose intolerance. Am Heart J. In press 2005.
18. Norhammar A, Tenerz A, Nilsson G, Hamsten A, Efendic S, Ryden L et al. Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: a prospective study. Lancet 2002;359:2140-4.
19. Weinberger MH, Fineberg NS, Fineberg SE. The influence of blood pressure and carbohydrate tolerance on vascular compliance in humans. Am J Hypertens 2002;15:678-82.
20. Williams B, Poulter NR, Brown MJ, Davis M, McInnes GT, Potter JF et al. Guidelines for the management of hypertension: report of the fourth working party of the British Hypertension Society, 2004-BHS IV. J Hum Hypertens 2004;18:139-85.
21. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998;317:703-13.
22. Lindholm LH, Ibsen H, Dahlof B, Devereux RB, Beevers G, de Faire U et al.; LIFE Study Group. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:1004-10.
23. Unwin N, Shaw J, Zimmet P, Alberti KG. Impaired glucose tolerance and impaired fasting glycaemia: the current status on definition and intervention. Diabet Med 2002;19:708-23.
24. Tominaga M, Eguchi H, Manaka H, Igarashi K, Kato T, Sekikawa A. Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study. Diabetes Care 1999;22:920-4.
25. Dinneen SF, Maldonado D 3rd, Leibson CL, Klee GG, Li H, Melton LJ 3rd et al. Effects of changing diagnostic criteria on the risk of developing diabetes. Diabetes Care 1998;21:1408-13.
26. Sowers JR. Epstein M. Diabetes mellitus and associated hypertension, vascular disease and nephropathy. Hypertension 1995;26:869-79.
27. Charles MA, Fontbonne A, Thibult N, Warnet JM, Rosselin GE, Eschwege E. Risk factors for NIDDM in white population. Paris prospective study. Diabetes 1991;40:796-9.
28. Herrington DM, Kesler K, Reiber JC, Davis W, Brown WV, Helms R et al. Arterial compliance adds to conventional risk factors for prediction of angiographic coronary artery disease. Am Heart J 2003;146:662-7.
29. Asmar R. Arterial stiffness and pulse wave velocity: clinical applications. Paris: Elsevier; 1999.p.135-42.
30. O'Rouke MF, Staessen JA, Vlachopoulos C, Duprez D, Plante GE. Clinical applications of arterial stiffness; definitions aaand reference values. Am J Hypertens 2002;15:426-44.
31. Van Bortel LM, Duprez D, Starmans-Kool MJ, Safar ME, Giannattasio C, Cockcroft J et al. Clinical applications of arterial stiffness, task force III: recommendations for user procedures. Am J Hypertens 2002;15:445-52.
32. Smith DH, Neutel JM. Change in arterial compliance as an early manifestation of hypertension. J Cardiovasc Risk 1997;4:267-70.
33. Soma I, Aakhus S, Dahl K, Slordahl S, Wiseth R, Wideroe TE et al. Hemodynamics in white coat hypertension compared to ambulatory hypertension and normotension. Am J Hypertens 1996;9:1090-8.
34. Boutouyrie P, Bussy C, Hayoz D, Hengstler J, Dartois N, Laloux B et al. Local pulse pressure and regression of arterial wall hypertrophy during long-term antihypertensive treatment. Circulation 2000; 101:2601-6.
35. Girerd X, Giannattasio C, Moulin C, Safar M, Mancia G, Lauerent S. Regression of arterial wall hypertrophy and improvement of carotid artery compliance after long term antihypertensive treatment: the pericles study. J Am Coll Cardiol 1998;31:1064-73.
36. Ting CT, Chen CH, Chang MS, Yin FCP. Short- and long-term effects of antihypertensive drugs on arterial reflections, compliance and impedance. Hypertension 1995;26:524-30.
37. Wahlqvist ML, Lo CS, Myers KA, Simpson RW, Simpson JM. Putative determinants of arterial wall compliance in NIDDM. Diabetes Care 1988;11:787-90.
38. Hopkins KD, Lehmann ED, Jones RL, Turay RC, Gosling RG. A family history of NIDDM is associated with decreased aortic distensibility in normal healthy young adult subjects. Diabetes Care 1996;19:501-3.
39. Weinberger MH, Fineberg NS, Fineberg E. The influence of blood pressure and carbohydrate tolerance on vascular compliance in humans. Am J Hypertens 2002; 15:678-82.
40. Tedesco MA, Natale F, Salvo GD, Caputo S, Capasso M, Calabro R. Effects of coexisting hypertension and type II diabetes mellitus on arterial stiffness. J Hum Hypertens 2004;18:469-73.
41. Stewart JT, Grbic M, Sigwart U. Left atrial and left ventricular diastolic function during acute myocardial ischaemia. Br Heart J 1992;68:377-81.
42. Kitzman DW, Gardin JM, Gottdiener JS, Arnold A, Boineau R, Aurigemma G et al.; Cardiovascular Health Study Research Group. Importance of heart failure with preserved systolic function in patients > or = 65 years of age. CHS Research Group. Cardiovascular Health Study. Am J Cardiol 2001;87:413-9.
43. Smith GL, Masoudi FA, Vaccarino V, Radford MJ, Krumholz HM. Outcomes in heart failure patients with preserved ejection fraction: mortality, readmission, and functional decline. J Am Coll Cardiol 2003;41:1510-8.
44. Rutter MK, Parise H, Benjamin EJ, Levy D, Larson M, Meigs JB et al. Impact of glucose intolerance and insulin resistance on cardiac structure and function: sex-related differences in the Framingham Heart Study. Circulation 2003;107:448-54.
45. Liu JE, Palmieri V, Roman MJ, Bella JN, Fabsitz R, Howard BV et al. The impact of diabetes on left ventricular filling pattern in normotensive and hypertensive adults: the Strong Heart Study. J Am Coll Cardiol 2001;37:1943-9.
46. Mayet J, Foale RA. Changes in left ventricular function in cardiac hypertrophy. In: Sheridan DJ, editor. Left ventricular hypertrophy. Edinburgh: Churchill Livingstone; 1998.p.93-9.
47. Sheridan DJ. The future. In: Sheridan DJ, editor. Left ventricular hypertrophy. Edinburgh: Churchill-Livingstone; 1998.p.201-2.
48. Koren MJ, Devereux RB, Casale PN, Savage DD, Laragh JH. Relations of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med 1991;114:345-52.
49. Verdecchia P, Schillaci G, Borgioni C, Ciucci A, Gattobigio R, Zampi I et al. Prognostic significance of serial changes in left ventricular mass in essential hypertension. Circulation 1998;97:48-54.
50. Muiesan ML, Salvetti M, Rizzoni D, Castellano M, Donato F, Agabiti-Rosei E. Association of change in left ventricular mass with prognosis during long-term antihypertensive treatment. J Hypertens 1995;13:1091-5.
51. Mosterd A, D'Agostino RB, Silbershatz H, Sytkowski PA, Kannel WB, Grobbee DE et al. Trends in the prevalence of hypertension, antihypertensive therapy, and left ventricular hypertrophy from 1950 to 1989. N Engl J Med 1999;340:1221-7.
52. Koren MJ, Ulin RJ, Koren AT, Laragh JH, Devereux RB. Left ventricular mass change during treatment and outcome in patients with essential hypertension. Am J Hypertens 2002;15:1021-8.
53. Fraser R. Studying genes and the development of cardiac hypertrophy: convenient intermediate phenotypes in man. J Hypertens 2003;21:873-4.
54. Bruno G, Giunti S, Bargero G, Ferrero S, Pagano G, Perin PC. Sex-differences in prevalence of electrocardiographic left ventricular hypertrophy in Type 2 diabetes: the Casale Monferrato Study. Diabet Med 2004;21:823-8.
55. Aepfelbacher FC, Yeon SB, Weinrauch LA, D'Elia J, Burger AJ. Improved glycemic control induces regression of left ventricular mass in patients with type 1 diabetes mellitus. Int J Cardiol 2004;94:47-51.
56. Van Hoeven KV, Factor SM. A comparison of the pathological spectrum of hypertensive, diabetic and hypertensive-diabetic heart disease. Circulation 1990;82:848-55.
57. Liu JE, Palmieri V, Roman MJ, Bella JN, Fabsitz R, Howard BV et al. The impact of diabetes on left ventricular filling pattern in normotensive and hypertensive adults: the Strong Heart Study. J Am Coll Cardiol 2001;37:1943-9.
58. Frustaci A, Kajstura J, Chimenti C, Jakoniuk I, Leri A, Maseri A et al. Myocardial cell death in human diabetes. Circ Res 2000;87:1123-30.
59. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998;317:703-13. Erratum in: BMJ 1999;318:29.
60. Lindholm LH, Ibsen H, Dahlof B, Devereux RB, Beevers G, de Faire U et al.; LIFE Study Group. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:1004-10.
61. Nakagami T, Qiao Q, Tuomilehto J, Balkau B, Carstensen B, Tajima N et al.; DECODA Study Group. Diabetes Epidemiology: Collaborative Analysis of Diagnostic criteria in Asia; International Diabetes Epidemiology Group. The fasting plasma glucose cut-point predicting a diabetic 2-h OGTT glucose level depends on the phenotype. Diabetes Res Clin Pract 2002;55:35-43. Erratum in: Diabetes Res Clin Pract 2002;58:73.
62. Barrett-Connor E, Ferrara A. Isolated postchallenge hyperglycemia and the risk of fatal cardiovascular disease in older women and men. The Rancho Bernardo Study. Diabetes Care 1998;21:1236-9.
63. Shaw JE, de Courten M, Boyko EJ, Zimmet PZ. Impact of new diagnostic criteria for diabetes on different populations. Diabetes Care 1999;22:762-6.
64. The DECODE study group on behalf of the European Diabetes Epidemiology Group. Is fasting glucose sufficient to define diabetes? Epidemiological data from 20 European studies. Diabetologia 1999;22:647-54.
65. Vaccaro O, Ruffa G, Imperatore G, Iovino V, Rivellese AA, Ricardi G. Risk of diabetes in the new diagnostic category of impaired fasting glucose. Diabetes Care 1999;22:1490-3.
66. Shaw JE, Zimmet PZ, de Courten M, Dowse GK, Chitson P, Gareeboo H et al. Impaired fasting glucose or impaired glucose tolerance. What best predicts future diabetes in Mauritius? Diabetes Care 1999;22:399-402.
67. Unwin N, Shaw J, Zimmet P, Alberti KG. Impaired glucose tolerance and impaired fasting glycaemia: the current status on definition and intervention. Diabet Med 2002;19:708-23.
68. Dinneen SF, Maldonado D 3rd, Leibson CL, Klee GG, Li H, Melton LJ 3rd et al. Effects of changing diagnostic criteria on the risk of developing diabetes. Diabetes Care 1998;21:1408-13.
69. Sowers JR, Epstein M. Diabetes mellitus and associated hypertension, vascular disease and nephropathy. Hypertension 1995;26:869-79.
70. Charles MA, Fontbonne A, Thibult N, Warnet JM, Rosselin GE, Eschwege E. Risk factors for NIDDM in white population: Paris Prospective Study. Diabetes 1991;40: 796-9.
71. Tominaga M, Eguchi H, Manaka H, Igarashi K, Kato T, Sekikawa A. Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Fungata Diabetes Study. Diabetes Care 1999;22:920-4.
72. Nakagami T, Qiao Q, Tuomilehto J, Balkau B, Carstensen B, Tajima N et al.; DECODA Study Group. Diabetes Epidemiology: Collaborative Analysis of Diagnostic criteria in Asia; International Diabetes Epidemiology Group. The fasting plasma glucose cut-point predicting a diabetic 2-h OGTT glucose level depends on the phenotype. Diabetes Res Clin Pract 2002;55:35-43. Erratum in: Diabetes Res Clin Pract 2002;58:73.
73. Bonora E. Postprandial peaks as a risk factor for cariovascular disease: epidemiological perspectives. Intern J Clin Practice 2002;129:5-11.
74. Meigs, JB, Larson MG, D'Agostino RB, Levy, D, Clouse ME, Nathan DM et al. Coronary artery calcification in type 2 diabetes and insulin resistance. The Framingham Offspring Study. Diabetes Care 2002;25:1313-9.
75. Giles RD, Yusuf S, Bourasa MG, Yi Q, Bosch J, Lonn EM et al.; on behalf of the HOPE Investigators. Effects of ramipril on coronary events in high-risk persons. Results of the Heart Outcome Prevention Evaluation Study. Circulation 2001;104:522-6.
76. Arnold JMO, Yusuf S, Young J, Mathew J, Johnston D, Avezum A et al.; on behalf of the HOPE Investigators. Prevention of heart failure in patients in the Heart Outcomes prevention Evaluation (HOPE) Study. Circulation 2003;107:1284-90.